JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million

Stock News

2025/11/17

JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.

The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1182754508"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182754508\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182754508?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 18:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182754508","market":"sg","top_or_hot":-1,"title":"JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million","media":"Stock News","content":"<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJBM HEALTHCARE (02161) Reports Interim Results: Profit Attributable to Equity Holders Rises 20.0% YoY to Approximately HK$115 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-17 18:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.</p>\n<p>The company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1182754508","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182754508","pubTimestamp":1763376026,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","02161":"健倍苗苗"},"translate_title":"健邦医疗(02161)公布中期业绩：权益持有人应佔溢利按年升20.0%至约1.15亿港元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02161":1},"content_text":"JBM HEALTHCARE (02161) announced its interim results for the six months ended September 30, 2025. Revenue reached approximately HK$430 million, representing a year-on-year increase of 7.7%. Profit attributable to equity holders rose by 20.0% YoY to around HK$115 million. Earnings per share stood at HK14.12 cents, with an interim dividend of HK9.75 cents per ordinary share.\nThe company attributed the growth to strong sales performance from its core brands, particularly Ho Chai Kung in the branded pharmaceutical segment and Po Chai Pills in the branded traditional Chinese medicine segment. This was driven by focused brand management and effective marketing execution. Additionally, the group's Chinese medicine formula granules business remained stable, contributing consistently to its branded healthcare product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}